Latest news and press releases about Intensity Therapeutics, Inc. (INTS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials.
Price
| Price | $3.81 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 10.80 |
| EV / EBITDA | -10.97 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -97.73% |
| Return on Invested Capital | -99.88% |
| Return on Assets | -82.31% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANTX · BOLD · IBIO · ITRM · NXTC · PLUR · PSTV
Explore sector: Healthcare · Biotechnology
More sections of INTS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks